Topic Antiinflammatory Therapy Added to Selective Photocoagulation in Macular Edema

Selective photocoagulation is the standard treatment for clinically significant macular edema. This treatment decreased the incidence of moderate visual loss in the long term. Nonetheless, in the first six weeks after treatment it is induced, probably because an exacerbation of macular edema secondary to treatment. An inflammatory response has been reported after selective photocoagulation. Therefore, antiinflammatory therapy like ketorolac or nepafenac could be useful to manage center point thickness secondary to selective photocoagulation in diabetics with macular edema.

Inclusion criteria

• type 2 diabetes
• regardless of diabetes duration and retinopathy severity level
• one or both eyes with focal clinically significant macular edema
• treated with selective or focal photocoagulation
• visual capacity under subjective refraction before treatment
• adequate quality 6mm fast macular map on the day of photocoagulation
• signed of inform consent

Exclusion criteria

• ocular surgery in the last 4 months
• previous selective photocoagulation
• topic or systemic antiinflammatory therapy in the last week
• allergic to antiinflammatory non-steroids therapy
• lent contact used in tha last 2 days before photocoagulation
• history of ocular trauma, ocular infection or lacrimal dysfunction in the last 3 months
• history of uveitis or ocular inflammation in the last 12 months
• any ocular external disease, infection or inflammatory process during evaluation
• corneal abnormalities that could modify visual capacity per se
• actual corneal disease
• pregnancy
• myopia over -6.00 diopters
• any retinal disease different from diabetic retinopathy
• adverse event of the drug
• desert to pharmacology therapy after the second visit
• no assistance after the second visit
• inadequate quality 6mm fast macular map after the second visit